OR WAIT null SECS
© 2021 MJH Life Sciences and Pharmaceutical Executive. All rights reserved.
© 2021 MJH Life Sciences™ and Pharmaceutical Executive. All rights reserved.
September 13, 2021
Landmark Bio CEO Ran Zheng talks about the value of collaborating with best-in-class partners.
Mark Davies and Paul Riley outline their blueprint for exploring how healthcare companies can leverage real-world evidence to access and engage customers more effectively.
August 30, 2021
Using the interview process to ensure high organizational standards.
August 11, 2021
With opportunity and risk lurking in equal measure, today’s key considerations for biopharma startups when building their leadership teams and product go-to-market strategies are outlined.
July 26, 2021
Biopharma deal-making is on the rise again and now is the time for biopharma companies to embrace M&As to prepare for future growth.
June 22, 2021
Pharma should be the ‘glue’ that bonds healthcare organizations together to solve society’s most pressing challenges.
May 19, 2021
Amgen board member and serial CEO Fred Hassan talks about the three levers Fortune 500 C-suites should consider as they position their firms from pilots to enterprise-wide digital transformation.
April 14, 2021
The “blank-check” method has emerged as a worthwhile bet for biopharma companies looking to raise capital and go public, but will its attractiveness fade along with the pandemic?
March 24, 2021
NJ can regain leadership in pharma by offering modern lab spaces for biotech and other lab-based growth companies.
March 19, 2021
Focusing on prevention, diagnosis, treatment, and care monitoring during the patient journey in oncology to create value for stakeholders.